



Fax completed form to: (855) 840-1678

If this is an URGENT request, please call (800) 882-4462
(800.88.CIGNA)

Zynyz (retifanlimab-dlwr)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
Urgency: ☐ Standard ☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
Medication requested: ☐ Zynyz 500mg/20mL solution for infusion ☐ other (please specify): ICD10: Directions for use: Dose: Quantity: Duration of therapy: Is this a new start? ☐ Yes ☐ No If yes, start date:					
Where will this medication be obtained? ☐ Accredo Specialty Pharmacy** ☐ Hospital Outpatient ☐ Retail pharmacy ☐ Other (please specify): ☐ Home Health / Home Infusion vendor ☐ Physician's office stock (billing on a medical claim form) **Cigna's nationally preferred specialty pharmacy					
**Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557					
Facility and/or doctor dispensing and administering medication: Facility Name: State: Tax ID#: Address (City, State, Zip Code):					
What is your patient's diagnosis? ☐ anal carcinoma ☐ squamous cell carcinoma of the anal canal (SCAC) ☐ Merkel cell carcinoma ☐ small bowel adenocarcinoma ☐ other (please specify):					

Clinical Information:

- (if Merkel cell carcinoma) Does the patient have metastatic or recurrent locally advanced disease? ☐ Yes ☐ No
- (if Anal Carcinoma) Will this medication be the only one used at this time to treat the patient's disease? ☐ Yes ☐ No
- (if no) Will this drug be used in combination with carboplatin and paclitaxel? ☐ Yes ☐ No
- (if Anal Carcinoma, if single agent) Will this medication be used prior to abdominoperineal resection? ☐ Yes ☐ No
- (if Anal Carcinoma, if single agent) Does your patient have locally recurrent, progressive disease? ☐ Yes ☐ No
- (if Anal Carcinoma, if single agent) Is this medication being used as first-line therapy or preferred second-line and subsequent therapy?
- ☐ First-line therapy
- ☐ Preferred second-line and subsequent therapy
- ☐ Neither of the above or Unknown
- (if Anal Carcinoma, if single agent) Does your patient have metastatic disease? ☐ Yes ☐ No
- (if Anal Carcinoma, if single agent) Has the patient received prior immunotherapy? ☐ Yes ☐ No
- (if Anal Carcinoma, if with carboplatin and paclitaxel) Will this drug be used as primary treatment of metastatic disease? ☐ Yes ☐ No
- (if Anal Carcinoma, if with carboplatin and paclitaxel) Will this drug be used as first-line treatment of metastatic disease if persistent or progressive locoregional disease? ☐ Yes ☐ No
- (if Small Bowel Adenocarcinoma) Will this medication be the only one used at this time to treat the patient's disease? ☐ Yes ☐ No
- (if Small Bowel Adenocarcinoma) Does your patient have a microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) disease?
- Notes: PLEASE NOTE: This is determined by immunohistochemistry (IHC) or microsatellite instability (MSI) testing. ☐ Yes ☐ No
- (if Small Bowel Adenocarcinoma) Does your patient have polymerase epsilon/delta [POLE/POLD1] mutation with ultra-hypermutated phenotype [for example, tumor mutational burden (TMB) with more than 50 mutations per megabase]? ☐ Yes ☐ No
- (if Small Bowel Adenocarcinoma) How is this drug being used?
- ☐ as primary treatment for locally unresectable or medically inoperable disease
- ☐ for advanced or metastatic disease
- ☐ Neither of the above or Unknown
- (if Small Bowel Adenocarcinoma) Has the patient received previous treatment with a checkpoint inhibitor, for any line of therapy? ☐ Yes ☐ No
- (if SCAC) Will this medication be used as first line therapy for inoperable locally recurrent or metastatic disease? ☐ Yes ☐ No
- (if yes) Will this medication be used in combination with carboplatin and paclitaxel? ☐ Yes ☐ No
- (if SCAC) Will this medication be used as single agent therapy for locally recurrent or metastatic disease? ☐ Yes ☐ No
- (if yes) Does the patient have disease progression on platinum-based chemotherapy -OR- intolerance to platinum-based chemotherapy? ☐ Yes ☐ No

Additional Pertinent Information: *(Please provide any additional clinical information that you feel is important to this review, including if the patient is currently taking the requested drug, including how they've been receiving it (samples, paying out of pocket, etc) and how long they have been on it with dates.):*

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

V081525